Treatment | Target | Year of EMA market authorisation for PsA |
IL antagonists | ||
Ixekizumab 80 mg SC Q2W | IL-17A | 2018 |
Ixekizumab 80 mg SC Q4W | ||
Secukinumab 150 mg SC Q4W | IL-17A | 2015 |
Secukinumab 300 mg SC Q4W | ||
Ustekinumab 45 mg SC Q12W | IL-12-p40 and IL-23-p40 | 2013 |
Ustekinumab 90 mg SC Q12W | ||
TNF-α inhibitors | ||
Adalimumab 40 mg SC Q2W | TNF-α | 2005 |
Certolizumab pegol 200 mg SC Q2W/400 mg SC Q4W | 2013 | |
Etanercept 25 mg SC BIW/50 mg SC Q1W | 2003 | |
Golimumab 50 mg SC Q4W | 2009 | |
Infliximab 5 mg/kg IV Q8W | 2005 | |
Other | ||
Abatacept 10 mg/kg IV Q4W | T-cell activation | 2017 |
Abatacept 125 mg SC Q1W | 2017 | |
Apremilast 30 mg PO BID | PDE4 | 2015 |
Tofacitinib 5 mg PO BID | JAK signalling pathway | 2018 |
BID, two times per day; BIW, twice weekly; IL, interleukin; IV, intravenously; JAK, Janus kinase; PDE, phosphodiesterase; PO, orally; PsA, psoriatic arthritis; QxW, every x weeks; SC, subcutaneously; TNF-α, tumour necrosis factor-α.